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Abstract To study autism outside of a narrow range of
settings previously studied, and in a particularly distinctive
setting in the Caribbean. The aim of the Aruba Autism
Project was to determine the prevalence of autism spectrum
disorders (ASDs) in birth years 1990–1999 in Aruba. A
record review study was conducted; cases were ascertained
from children treated at the Child & Adolescent Psychiatry
Clinic of Aruba, the first and only child psychiatry service
on the island. In these 10 birth years we found a prevalence
for autistic disorder (AD) of 1.9 per 1,000 (95% CI 1.2–2.8)
and for autism spectrum disorders of 5.3 per 1,000 (95% CI
4.1–6.7). Comparison analysis with a cumulative incidence
report from the UK, showed a similar cumulative incidence
to age five in Aruba. Prevalence of ASDs in birth years
1990–1999 and cumulative incidence to age five in Aruba
are similar to recent reports from the United Kingdom and
the United States.
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Significant Outcomes:
•This first epidemiologic study on ASD in the Caribbean shows
prevalence estimates and gender distribution similar to those reported
in recent studies in the UK and US.
•Comparison analysis with a study of cumulative incidence of AD and
ASD in the UK showed a cumulative incidence rate in the youngest
age group in Aruba at the high end of the confidence interval of that in
the UK.
Limitations:
•Only children who presented for clinical assessment and elicited
clinical suspicion of falling within the autism spectrum are included in
the prevalence estimate.
•Cases born in the early 1990s may have emigrated in search of
services prior to the clinic’s opening.
•Higher functioning cases born in the late 1990s may not have attained
a sufficient age for referral.
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Autism spectrum disorders (ASDs) are developmental
disorders, characterized by impairments in social function-
ing, communication and behavior. Reports of worldwide
prevalence figures since the 1990’s contributed to intensi-
fied research efforts [1, 2], but the descriptive epidemiology
of ASDs remained incomplete, as concern over potential
environmental causes continued to increase [3].
For decades available data derived from prevalence
studies in developed countries conducted in a narrow range
of settings [1]. Current prevalence estimates of ASDs in
these settings fall in the range of 3–12 per 1,000 [4–8].
Autism specific epidemiologic research outside of the
narrow range of these first world high-income countries
has only recently been addressed [9–11]. The current
project contributes to the expansion of autism specific
epidemiologic research in increasingly diverse settings.
This study is the first attempt to study the epidemiology
of ASDs in the Caribbean, using methods that allow
comparisons with other studies. Aruba is uniquely suited
for this purpose, as it has a culturally distinct, heteroge-
neous, multilingual and ethnically mixed population.
Furthermore, Aruba has a well-established health care
system, one centralized child psychiatry clinic and a
population registry providing both the means to identify
disabled children, and to enumerate the island population.
Previous psychiatric epidemiologic research in rare
disorders in the same region (the Netherlands Antilles)
has shown that such research is feasible [12, 13].
Aims of the study were to determine the prevalence for
ASDs in birth years 1990–1999 in Aruba, and to conduct a
comparison analysis with a cumulative incidence report
from the UK. We performed the study because examining
prevalence of autism across diverse settings might provide
clues to either genetic or environmental etiologies.
Material and methods
Area and population
Aruba, a Caribbean island 17 miles off the coast of
Venezuela, is a separate, autonomous member of the
Kingdom of the Netherlands. Since 1990, the population
of Aruba increased nearly 37% through immigration to
90,506 inhabitants in 2000. The population of Aruba is
predominantly of Amerindian (Arawak), Dutch, and Span-
ish ancestry [14]. While there may be social distinctions
based on race, these are nowhere documented, and race is
officially considered a continuously distributed trait.
In some ways Aruban health characteristics such as life
expectancy, leading causes of death, and infant mortality
are similar to those of the UK, the Netherlands, and the US
[15–17].
During the 1990’s health insurance was nearly universal
for legal residents, although access to specialty services was
limited. After the introduction of a mandatory universal
health insurance system in 2001 for legal residents, access
to health care in Aruba improved further. Children are
entitled to health care based on legal residency of parents.
The insurance premium is income-dependent up to a certain
maximum and paid by employers, employees and the
government.
Study population
The Aruba Autism Project was carried out at the Child and
Adolescent Psychiatry (CAP) Clinic of Aruba, an outpatient
clinic established in 1997. The clinic was the first and only
child psychiatry service on the island. Before its establish-
ment no child psychiatry expertise or services were locally
available to the community. Children could be referred to
the service by general practitioners, pediatricians or other
medical specialists. Virtually all Aruban-born children
within the psychiatry service were legal residents.
This study is based on children born in Aruba from
January 1, 1990 through December 31, 1999 and seen at the
Child and Adolescent Psychiatry Clinic between May 1,
1997 and December 31, 2003.
All clinical files for the period from the establishment of
the clinic from May 1, 1997 until December 31, 2003 were
reviewed for the study. In this six and a half year period the
clinic evaluated a total of 1,543 patients, including 813
Aruban children born in the targeted years (see Fig. 1).
Fig. 1 Study sample
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Clinic charts of children born in the targeted birth years
(N=813) were systematically screened, and the records of
potential cases abstracted (N=75). Study diagnoses were
assigned based on abstracted data.
Clinical records
Clinical notes and DSM-IV symptoms were recorded by the
one clinic child psychiatrist (IvB) over the entire study
period. The clinic psychiatrist was trained as a child
psychiatrist in the Netherlands, where she did residencies
in pediatrics, genetics, psychiatry and child psychiatry. She
has expertise in developmental and genetic syndromes [18–
20], and is certified in the use of standardized assessment
instruments for research diagnosis of ASDs. Standardized
forms were completed on every child at intake. Intake
included collection of medical, developmental, school and
family histories; as well as information on current clinical
symptoms. Diagnostic assessments were rarely concluded
in one visit. Child psychiatric assessments and behavioral
observations would typically take place at second and third
follow up visits. Results of routine psychological assess-
ments performed at intake or during the course of treatment
were also recorded, as were notes from consultations with
other experts.
At the clinic a ‘suspected’ ASD diagnosis was given
when clinical symptoms did not (yet) meet all the criteria
necessary for a definite diagnosis of a pervasive develop-
mental disorder. A ‘suspected’ diagnosis made support and
intervention possible, while allowing parents time to adjust,
and the symptomatology to fully emerge over time [21].
For the study the clinical cases with a ‘suspected’ ASD
diagnosis were subject to review and not automatically
included in the numerator of prevalence figures. If a
suspected case was assigned an ASD study diagnosis—
based on the presence of DSM symptoms in the chart
notes—then he/she was included as a case in the
prevalence figure.
Charts with an ASD diagnosis (Autistic Disorder,
Asperger’s Disorder, Pervasive Developmental Disorder
Not Otherwise Specified, Rett’s Disorder, or Childhood
Disintegrative Disorder), or an ASD diagnosis “suspected”
with no subsequent diagnosis ruling out spectrum diagno-
ses, were flagged and abstracted by a Dutch resident of
psychiatry (MV).
Record review and study diagnosis
Evidence of DSM-IV symptoms was abstracted from the
charts; subsequently a computer algorithm was applied. The
algorithm was consistent with DSM-IV symptom list
ratings for ASDs. Study inclusion was based on standard-
ized chart abstractions; a study diagnosis was assigned in
accordance with standardized diagnostic criteria.
A study diagnosis of Autistic Disorder (AD) required
chart evidence of two or more social criteria, one or more
communication criteria, and one or more behavioral criteria
for autism, totaling six or more criteria across the three
symptom domains, with a delay or abnormal functioning
onset before age three in at least one of three areas—social
interaction, language used in social communication, sym-
bolic or imaginative play. The Asperger’s Disorder (AS)
classification required chart evidence of two or more social
criteria for autism, one or more behavioral criteria for
autism, normal language development (single words by
24 months, phrase speech by 36 months), and absence of
mental retardation and autistic disorder. Pervasive Devel-
opmental Disorder-Not Otherwise Specified (PDD-NOS)
classification required one or more social criteria, and one
or more communication criteria for autism or one or more
behavioral criteria for autism in the absence of other
diagnosable autism spectrum disorders. An Autism Spec-
trum Disorder (ASD) classification was also applied to
those classified with AD, AS or PDD-NOS.
Mental retardation
Mental retardation (MR) was diagnosed based on chart
records of IQ measurements. When children were unequiv-
ocally MR (N=15), they received a clinical diagnosis of
MR and were not tested (22%). Measurements were
available in 54 of the study diagnosed cases (78%): in 40
cases the children had a normal test-based IQ, while 14
children (20%) had been tested as mentally retarded (IQ<
70). In total 29 of the 69 cases were mentally retarded
(42%).
Validation study
To validate study classification of ASD, the Autism
Diagnostic Observation Schedule (ADOS) was used. The
ADOS is a semi-structured, standardized assessment of
communication, social interaction and imaginative play for
individuals suspected of having an Autism Spectrum
Disorder [22, 23].
The subjects included 24 children with a study diagnosis
of ASD, and six clinic children diagnosed with other
disorders. Selection of non-ASD clinic children was based
on random identification in the computerized patient list.
This list was restricted to active patients, excluding children
who had previously screened positive for our study. To
prevent possible selection bias the secretary of the clinic
invited parents from a list of children with regular follow-
up visits to the clinic in preceding weeks, working down
J Neurodevelop Disord (2009) 1:197–204 199the list until six children were selected. The selected
children were born 1993–1999.
Most subjects in the validation study were assessed by
an independent ADOS certified rater from the neighboring
island of Curaçao. When this rater was not available,
children were assessed by the first author.
Confidentiality
In keeping with Dutch medical ethical guidelines for the
conduct of record review studies, personal information was
treated confidentially. Only the treating child psychiatrist
and the research psychiatrist had access to the medical
charts. Data were entered into a statistical database without
identifying information.
Population data
Data on registered births and population characteristics
were obtained from the Central Bureau of Statistics, Aruba.
All births to legal residents are registered. During the years
1990–1999 there were 13,109 registered births (6,755
males and 6,354 females) [24].
Analysis
Main prevalence analysis
Prevalence estimates were calculated as the number of
cases identified among children born in Aruba between
1990–1999 divided by total registered live births 1990–
1999. We used the Poisson distribution to calculate 95%
confidence intervals [25].
Statistical comparison of the proportion with mental
retardation among the diagnostic groups (AD versus PDD-
NOS) was assessed with Pearson Chi Square.
Comparison analysis of cumulative incidence
The published study most similar to the Aruba study in
methodology and birth years was conducted by Powell et
al. 2000 [26] in two areas of the West Midlands, UK. To
compare our data to those described by Powell et al.,
2000, we calculated cumulative incidence of AD and
ASDs in children with first service contact prior to age
five, and born in the period January 1, 1996 through
December 31, 1998. Children in these birth years had
access to the psychiatric service at least from ages one
through 5 years. The cumulative incidence is calculated by
the number of Aruban born children 1996–1998 with an
intake prior to age five assigned a study diagnosis of ASD,
divided by the total number of children born in Aruba
between 19960–1998.
Results
Characteristics of the screened positive children
A total of 813 children born in Aruba from 1990 through
1999 were identified in the Child and Adolescent Psychi-
atry Clinic records; of these 75 children screened positive.
Among the screen positive 60% of children were
referred by GP’s, 30.7% were referred by pediatricians
and 9.3% by other specialists. The most common reasons
for referral were behavioral problems (61.3% of children)
and speech and/or language delay (45.3% of children).
Other reasons for referral were impaired relatedness
(34.7%), mental retardation (4%), attentional problems,
eating problems, sleeping disorder, or anxiety. In total
54.6% of children had more than one reason for referral.
Main prevalence findings
Sixty-nine of the screen positive children were assigned a
study classification of ASD. 25 (36.2%) were classified as
AD, 2 (2.9%) were classified as AS, and 42 (60.9%) were
classified as PDD-NOS. No cases with regression in
development, Childhood Disintegrative Disorder or Rett’s
Disorder were identified. The overall prevalence of ASDs
was 5.3 (95% CI 4.1–6.7) per 1,000 births. Details
concerning prevalence are shown in Table 1.
Case characteristics
Clinicalcharacteristicsofthe69casesarepresentedinTable2.
The proportion of study-defined MR in AD was 64.0%, in
PDD-NOS 29.3% and overall ASDs 41.2%. The difference
in percentages of children with mental retardation between
AD and PDD-NOS is significant (χ
2=7.670; df=1; p<.01).
Boys outnumbered girls by 7.3:1 for AD, and 7.4:1 for PDD-
NOS. Mean age at intake overall was 5.5 years (SD=2.2). In
children born from 1990–1994 (minimum possible intake
age in the first year the clinic was opened: 3–7y e a r s )t h e
mean age at intake was 7.2 years (SD=2.1). In this group,
there was no significant difference in age at intake between
children classified as AD and children classified as PDD-
NOS. For children born 1995–1999 (minimum possible
intake age in the first year the clinic was opened: 0–2y e a r s )
the mean age at intake was 4.5 years (SD=1.5). In this
group, children classified as AD were significantly younger
than children classified with PDD-NOS (3.9 years versus
5.1 years; t=−2.67; df=41; p<.05).
Validation study
The subjects for the validation study included 24 children
with a study diagnosis of ASD, and six clinic children
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blinded to diagnostic information prior to the assessment,
and assessed 17 of the 24 (70%) of ASD study cases with
the ADOS, while the remaining seven ASD subjects were
examined by the first author (IvB). All except one (95.8%
of 24) of the study diagnoses of ASD were confirmed by
the ADOS rating. None of the children diagnosed with
other disorders scored for ASD on the ADOS algorithm.
Comparison analysis of cumulative incidence
To compare our data to those described by Powell et al.,
2000 [26], we calculated the cumulative incidence in
children born in the period January 1, 1996 through
December 31, 1998, with intake prior to age five. The
cumulative incidence for AD was 2.4 per 1,000 (95% CI
1.1–4.4) and for all ASDs it was 4.5 per 1,000 (95% CI
2.7–7.0). Powell reported a cumulative incidence to age
five of 1.6 per 1,000 (95% CI 1.1–2.4) for AD, and 3.4 per
1,000 (95% CI 2.5–4.4) for ASDs.
Discussion
This is the first report of the prevalence of autism spectrum
disorders in a Caribbean country. In the Aruba birth years
1990–1999 we found a prevalence for autistic disorder of
1.9 per 1,000 (95% CI 1.2–2.8) and for autism spectrum
disorders of 5.3 per 1,000 (95% CI 4.1–6.7). These
prevalence estimates should be considered minimum
prevalence. Centralized psychiatric services, with excellent
coverage and penetration notwithstanding, it is possible that
ASD cases have escaped detection within the study period.
Children who have left the frame of observation may have
been missed cases, but they still were included in the
denominator. Higher functioning cases and young children
(i.e. year of birth in the late nineties) may not have been
referred.
The prevalence found in the present study is in the mid
range of estimates reported for similar birth years in studies
conducted in the US and Europe, using diverse methodol-
ogies [4–8, 27–31]. In Table 3 we present selected autism
prevalence studies published from 2000 reporting on
children born during the same time period, but diagnosed
using varied methodologies.
The Aruban findings are consistent with these reports in
two additional respects: the proportion of autism spectrum
cases with AD (25/69=36.2%), and the proportion of cases
with co-morbid mental retardation (41% ASDs, 64% AD).
The sex ratio (87.0% males) is also within the range of
previous reports [1, 5, 7, 8, 30].
The validation study showed a rate of agreement
between study diagnosis and ADOS that was higher than
expected at 95.8%. For example, Gray et al. [32] showed
that the overall agreement between ADOS and clinical
diagnosis was .87 (95% CI .81–.91) in a group of young
children (aged 20–55 months). A possible explanation for
the higher agreement found in the present study could be
the preponderance of AD (16 of 24 subjects), and a higher
age distribution; both conditions contribute to a better
performance of the ADOS [32, 33].
A recent epidemiological study investigating children
aged 3–9 years within different health services in Venezuela
[34] yielded a treated prevalence of 1.7 per 1,000 (95% CI
0.1–2.0) for all ASDs, and 1.1 per 1,000 (95% CI 1.0–1.4)
for autism. There could be various explanations for the
markedly lower prevalence estimates in Venezuela, espe-
cially for all ASDs, compared to our study. Aruba is
Diagnosis Male 95% CI Female 95% CI Total 95% CI
AD 3.3 2.0–4.9 0.5 0.1–1.4 1.9 1.2–2.8
PDD-NOS 5.5 3.9–7.5 0.8 0.3–1.8 3.2 2.3–4.3
Asperger 0.1 0.0–0.8 0.2 0.0–0.9 0.2 0.0–0.6
Total ASD 8.9 6.8–11.4 1.4 0.6–2.7 5.3 4.1–6.7
Table 1 Prevalence per 1,000
births
AD (n=25) PDD-NOS (n=42) ASDs (n=69)
SYMPTOMS (range) Mean (sd) Mean (sd) Mean (sd)
Social (0–4) 3.8 (0.5) 2.7(1.0) 3.1(1.0)
Communication (0–3) 2.2(0.7) 1.5(0.8) 1.7(0.9)
Repetitive Behaviours (0–4) 2.2 (1.1) 0.3(0.6) 1.0(1.2)
Total Symptoms 8.2 (1.6) 4.5 (1.3)
a 5.8 (2.3)
AGE AT INTAKE—years 4.6 (2.3) 6.0 (1.9) 5.5 (2.2)
Birth cohort 1990–1999
MENTAL RETARDATION—% 64.0% 29.3% 41.2%
Table 2 Case characteristics
aOnly one case meeting study
criteria of PDD-NOS had the
minimum number of two symp-
toms; all other cases had three or
more symptoms
J Neurodevelop Disord (2009) 1:197–204 201distinctly different from Venezuela, not only in terms of
availability and access to health care, but also with respect
to socioeconomic and population characteristics. One
explanation is a lower degree of service coverage and
penetration in the population compared to the Aruba study,
where 6% of all children born in Aruba between 1990–
1999 were evaluated at the clinic. As mentioned by the
authors, a possible lack of awareness of autism and
treatment options in the general population could have
resulted in underrecognition and lower referral levels for
higher functioning ASD cases. Of course, lower prevalence
estimates can also reflect lower prevalence in the underly-
ing population.
Because epidemiologic findings with respect to autism
spectrum disorders are particularly sensitive to study
methodology, the comparison analysis was undertaken in
which we drew a direct comparison of cumulative
incidence to age five of ASDs in Aruba to that reported
by a study conducted in two areas of the West Midlands,
UK [26]. In this UK study case ascertainment methods are
similar to the present study: children were identified
through Child Developmental Centres’ treatment records,
and similar diagnostic criteria were in use during the period
of case detection. Powell reported a cumulative incidence
(to age five) of 1.6 per 1,000 for AD, and 3.4 per 1,000 for
ASDs. We estimated the cumulative incidence to age five of
AD and ASDs to be 2.4 per 1,000, 4.5 per 1,000
respectively, at the high end of the confidence intervals of
the UK study. This difference may be one of methodology.
In the UK study onset was defined as the age at which a
definite or probable diagnosis of ASD was first communi-
cated to the child’s family, whereas in the present study we
used date of first contact. However, it is uncertain whether
this slightly higher cumulative incidence could be
accounted for by this difference.
The ideal study upon which to base comparisons in
prevalence and cumulative incidence across cultures would
use the same rigorous methods at all research sites.
However, in reality the development of comparable
prevalence estimates is hampered by methodological issues,
and differences across countries and services.
It was therefore surprising that in spite of stated
differences we found, using similar methods, that the
prevalence estimate for ASDs previously reported in a
narrow range of countries, also pertains in a place as
distinctive as Aruba.
Strengths and limitations of the study
The strength of evidence derives from the coverage and
penetration of the health care system, the quality of
diagnostic services, and the ability to accurately enumerate
the population at risk. During the 1990’s, health insurance
was nearly universal for legal residents, but access to
specialty services was limited. From 2001 forward, access
to child psychiatry services was effectively universal; over
the study period, six percent of all children born in Aruba
from 1990 to 1999 were assessed at the clinic.
Table 3 A comparison of selected descriptive epidemiology studies of autism
Powell et al.
2000 [26]
Baird et al.
2000 [27]
Bertrand et al.
2001 [28]
Yeargin-Allsop et al.
2003 [31]
Chakrabarti and
Fombonne 2005 [29]
van Balkom et al.
Present study
Population 16,012
b 16,235 8,896 289,456 10,903 13,109
Country UK UK US US UK Aruba
Age 1–4 years 7 years 3–10 years 3–10 years 4–6 years 4–13 years
Diagnosis
a RD DA DA RRD DA RRD
Prevalence
AD
1.6
b 3.1 4.0 – 2.2 1.9
Prevalence
ASDs
3.4
b 5.8 6.7 3.4 5.9 5.3
Proportion 48% 53% 60% – 38% 36%
AD/all
ASDs
(26/54) (50/94) (36/60) (24/64) (25/69)
Male:
Female
ASDs
5.7:1 7.5:1 2.8:1 4:1 6.1:1 (est) 6.7:1
% MR: AD – 40% 58% – 67% 64%
% MR:
ASDs
– 22% 49% 64% 30% 42%
Legenda
aDA Direct Assessment; RD Record Diagnosis; RRD Record Review Diagnosis,
bCumulative incidence single birth year ≈ lifetime prevalence to
age 5 for birth year
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the prevalence estimates are based also contribute to the
strength of the study findings. All children were fully
assessed by the clinic psychiatrist and detailed clinical notes
were systematically collected and included in charts. Study
inclusion was based on standardized chart abstractions; a
study diagnosis was assigned in accordance with standard-
ized diagnostic criteria. In an effort to validate study
classification of ASD the ADOS was used to examine 35%
(24/69) of ASD subjects included in the study. This showed
confirmation of study classification in all cases, but one.
Finally, the population of Aruban births 1990–1999 was
enumerated based on population registry data. Because
virtually all births in Aruba are attended [15], registry data
should include the births of all legal Aruban-born children.
All children identified with ASDs reported here are legal
Aruban residents.
The limitations of this study are those common to
record-based prevalence studies, and fall into two principal
categories: factors affecting case ascertainment and factors
affecting diagnosis. With respect to case ascertainment, a
fundamental limitation of record review methodology is
that prevalence will only include children who presented
for clinical assessment, and who elicited clinical suspicion
of falling within the autism spectrum. In past studies,
reliance on a single source for identifying cases has yielded
low estimates [31]. In this Aruban context, diagnostic
assessment and treatment is centralized in the first and only
child psychiatry service on the island; competing diagnostic
services do not exist.
Other ascertainment effects are specific to segments of
the cohort, and are only relevant in the context of the main
prevalence analysis. Some cases among children born in
the earliest birth years and in the latest birth years may not
have been referred to the child psychiatric service.
Because the clinic opened in 1997, it is possible that
cases born in the early 1990s emigrated in search of
services prior to the clinic’s opening and thereby escaped
detection. It is also possible that higher functioning cases
born in the late 1990s have not attained a sufficient age for
referral and are therefore underrepresented in this study.
Another ascertainment issue may be relevant to both
the main prevalence analysis and the comparison analysis,
that is that ascertainment of children with prominent co-
morbidities, especially mental retardation, may also have
been limited. Interviews with directors of Aruban schools
and day-care programs for the disabled concerning the
diagnostic distribution in their institutions, however, lead
us to believe that few lower functioning children were
overlooked.
With respect to diagnosis, as in any record-based study,
the findings are limited by the absence of in-person
standardized research interviews and assessments of every
study classified case. Due to restraints in time and
finances only 24 of the 69 children (almost 35%) with a
study classification of ASD were assessed with the ADOS.
One study classified ASD case was not confirmed by the
ADOS rating.
A potential for misdiagnosis specific to this population
arises from the multilingual environment. It is possible that
some children with late language development and behav-
ioral disturbances (e.g., ADHD) present with ASD-like
profiles at some point in their development.
In conclusion, it is clear that interest in the distribution of
ASDs is intensifying, as concern over possible environ-
mental contributions to the occurrence of these disorders
continues to grow [3]. Standardizing future research
methodology would permit geographic cross-cultural com-
parisons. Finding areas of high and low contrast will also
motivate additional international epidemiologic investiga-
tions. In addition, each epidemiologic study will contribute
to local appreciation of the magnitude of ASDs impact on
local public health resources and services.
This study shows that the prevalence of ASDs in Aruba
is similar to previous prevalence reports from a narrow
range of developed countries. We hesitate to draw infer-
ences about the causes of autism based on findings from a
single setting. However, as studies in diverse settings
accumulate, we believe that the emerging picture will
provide important clues to some causes and help to rule
out others. The significance of these findings for Aruba is
clear. Aruba joins the developed world in needing to
respond with services and care for a significant number of
seriously disabled individuals.
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